Feminizing adrenocortical carcinoma with Cushing's syndrome and pseudohyperparathyroidism.
A patient with adrenocortical carcinoma had three major endocrine abnormalities attributable directly to the tumor: hypercortisolism (Cushing's syndrome), hyperestrogenism (feminization), and hypercalcemia (pseudohyperparathyroidism). There were higher levels of immunoreactive parathyroid hormone in venous effluent from the tumor or its abdominal metastases compared to that found in the veins draining the parathyroid glands. This, together with the presence of normal parathyroid glands on autopsy, established the diagnosis of pseudohyperparathyroidism as the cause of hypercalcemia in this patient.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000306:Adrenal Cortex Neoplasms / Q000150:complications* / Q000188:drug therapy; D000310:Adrenal Gland Neoplasms / Q000150:complications*; D000328:Adult; D000616:Aminoglutethimide / Q000627:therapeutic use; D000735:Androstenedione / Q000097:blood; D003480:Cushing Syndrome / Q000209:etiology*; D003907:Dexamethasone / Q000627:therapeutic use; D004967:Estrogens / Q000097:blood; D005262:Feminization / Q000209:etiology*; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology*; D008297:Male; D008797:Metyrapone / Q000627:therapeutic use; D008939:Mitotane / Q000627:therapeutic use; D009384:Paraneoplastic Endocrine Syndromes / Q000150:complications* / Q000188:drug therapy; D010281:Parathyroid Hormone / Q000097:blood; D013739:Testosterone / Q000097:blood
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D004967:Estrogens; D010281:Parathyroid Hormone; D000616:Aminoglutethimide; D013739:Testosterone; D000735:Androstenedione; D008939:Mitotane; D003907:Dexamethasone; D008797:Metyrapone